• EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer
  • Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery
  • FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers
  • FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
  • Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer
  • Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial
  • Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says
  • Merck to Launch Ontruzant, a Herceptin Biosimilar, in US
  • Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases
  • 3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic
  • Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say
  • Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland